Innovent Biologics (IVBXF) Stock Price, News & Analysis

Company Overview

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar). Innovent’s late-stage pipeline also features additional immuno-oncology candidates, fusion proteins and antibodies targeting autoimmune and ophthalmologic diseases. Its state-of-the-art manufacturing facilities in Suzhou are designed to meet global regulatory standards and support both domestic supply and international partnerships.

Since its initial public offering on the Hong Kong Stock Exchange in 2018, Innovent has entered strategic collaborations with multinational pharmaceutical companies, including partnerships with Eli Lilly for sintilimab and with Boehringer Ingelheim for other pipeline assets. The company primarily serves the Chinese market while pursuing registration and commercialization opportunities across Asia Pacific and select global territories. Under the leadership of founder and CEO Dr. Michael Yu, Innovent continues to expand its clinical development footprint and strengthen its manufacturing capacity to address unmet medical needs worldwide.

Key Stats

• Today's Range: $10.74 to $11.98
• 50-Day Range: $9.10 to $12.96
• 52-Week Range: $9.10 to $15.12
• Volume: 734 shs
• Average Volume: 4,220 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/01/2026
• Next Earnings (Estimated): 8/26/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:IVBXF
• CIK: 1774163
• Web: www.innoventbio.com
• Phone: 86-512-6956-6088
• Fax: N/A
• Employees: 4,872
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A